Gilead Sciences licensed a clinic‑ready MAT2A inhibitor from Suzhou‑based Genhouse Bio in a deal that could total up to $1.53 billion. The agreement gives Gilead access to GH31, a candidate targeting synthetic lethality in MTAP‑deleted tumors, with IND clearance already filed in the U.S. and China. Genhouse will receive an upfront payment and is eligible for development, regulatory and commercial milestones plus tiered royalties. Gilead said the therapy expands its oncology portfolio into metabolic synthetic‑lethality approaches and complements its existing targeted programs. The transaction highlights continued Big Pharma interest in Asia‑originated assets and in synthetic‑lethality strategies that aim to exploit tumor‑specific vulnerabilities. The deal also signals cross‑border sourcing remains a core M&A and licensing vector for pipeline replenishment.